Writings
Retatrutide vs. Ozempic: 6 Things I Tell Patients Who Ask
Originally published on Substack.
The top reply under my retatrutide post this week was one honest sentence: “Is it the drug or just the weight loss?” If you’re on Ozempic, or wondering whether to wait for something stronger, that question is yours too. Here is the short answer, and the six things I tell every patient who asks.
On October 28, Eli Lilly released top-line results from TRANSCEND-T2D-2, the first Phase 3 trial to put retatrutide head-to-head against another incretin drug. Retatrutide is one weekly shot that hits three hormone receptors (GIP, GLP-1 and glucagon). Ozempic hits one.
1. The numbers are big. 1,298 adults with type 2 diabetes, starting around 225 pounds, were randomized to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg, the highest approved dose, for 80 weeks. Weight fell 19.5% and 20.9% on retatrutide versus 9.4% on Ozempic. A1C fell 2.2 versus 1.8 percentage points (from 8.3%). What I tell patients: this is the strongest head-to-head weight result I’ve seen in diabetes.
2. It’s a press release, not a paper. These are company-reported numbers, and the “efficacy estimand” counts people as if everyone stayed on the drug. Full results are promised at a future meeting and in a peer-reviewed journal. What I tell patients: real-world numbers usually come in lower. Wait for the paper.
3. The trial was open-label. Everyone knew which drug they were on. That matters less for a scale reading, more for side-effect reporting. What I tell patients: strong signal, not the final word.
4. More people quit. Stopping for side effects: 4.8% and 7.9% on retatrutide versus 2.7% on Ozempic. Dysesthesia, an odd skin sensation, showed up in 4.8% and 6.5% versus 2.7%. Lilly says most side effects were mild to moderate. What I tell patients: more power usually means more people who can’t tolerate it.
5. We can’t tell yet whether it’s the drug or the weight loss. That’s the honest answer to your question. Lilly reports better blood pressure, triglycerides and non-HDL cholesterol, but there are no heart attack or stroke outcome data yet. Semaglutide already has them: in SELECT (NEJM 2023), 17,604 adults with heart disease and overweight or obesity without diabetes, on semaglutide 2.4 mg, had 20% fewer major cardiac events. What I tell patients: for your heart, proven beats promising, for now.
6. It is not approved. Don’t buy it online. Retatrutide is not approved by the FDA or any regulator anywhere, and Lilly says anyone selling it to consumers is breaking the law. Two deaths after black-market or compounded retatrutide have been reported to the FDA’s adverse event system. The source says the products were likely bootleg, and those reports don’t prove the drug caused the deaths. What I tell patients: a vial labeled “research use only” is not a shortcut. It’s a gamble with your heart.
If you qualify for treatment today, ask your doctor about approved options. Then protect your muscle: enough protein and resistance training two or three times a week, because the scale doesn’t tell you what you’re losing.
The best drug is the one you can take safely for years, not the one with the biggest headline.
Would you switch if retatrutide is approved, or stay on what’s working? Tell me in the comments.
This is education, not medical advice.
Blessings, Ash
More at DoctorEmrani.com
Further reading: Eli Lilly, TRANSCEND-T2D-2 top-line release, Oct 28, 2026 (NCT06260722); Lincoff et al., SELECT, NEJM 2023;389:2221-2232; Partnership for Safe Medicines, Oct 19, 2026 (citing CBS News, FAERS reports).
